As of November 6, 2026, Akari Therapeutics Plc is a publicly traded company (Nasdaq: AKTX). The largest holder reporting an active stake on Schedule 13D is Samir Patel, a director, at 10.4%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Hoyoung Huh, a director (18.4%, reporting on Schedule 13G); Ray Prudo, a director (8.9%) (Schedule 13D/A, March 4, 2026).
Is this your company?
About to sign with, pay or invest in Akari Therapeutics Plc? See the free Snapshot first.
Free to see. No signup.
Is Akari Therapeutics Plc a real, registered company?
- Akari Therapeutics Plc files with the SEC under CIK 1541157 (its SEC filings).
- Its shares are listed under the ticker AKTX on Nasdaq (SEC company record).
- Incorporated in X0; business address in Tampa, Florida, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Akari Therapeutics Plc in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Bank of Montreal (filed 2026-08-12).
Who are Akari Therapeutics Plc's owners and officers?
Akari Therapeutics Plc: business address in Tampa, Florida; industry Pharmaceutical Preparations (Schedule 13G, 2026-08-12).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-06-03)
- : Executive Officer (Form D, 2026-06-03)
- : Director (Form D, 2026-06-03)
- : Director (Form D, 2026-06-03)
- : Director (Form D, 2026-06-03)
- : Director (Form D, 2026-06-03)
- : Director (Form D, 2026-06-03)
- : Director (Form D, 2026-06-03)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-12 | Bank Of Montreal | 5.71% |
| Schedule 13G, 2026-08-07 | White Lion Capital LLC | 5% |
| Schedule 13G, 2026-06-08 | Mmcap International Inc. Spc | 8% |
| Schedule 13G/A, 2026-03-04 | Hoyoung Huh, M.D., Ph.D. | 18.4% |
| Schedule 13D/A, 2026-03-04 | Ray Prudo, M.D. | 8.9% |
| Schedule 13D/A, 2026-03-04 | Samir R. Patel | 10.4% |
Questions about who owns Akari Therapeutics Plc
Who owns Akari Therapeutics Plc?
On this page, 6 holders' latest ownership filings report 5% or more of Akari Therapeutics Plc: Hoyoung Huh, M.D., Ph.D. (18.4%, Schedule 13G/A, filed 2026-03-04), Samir R. Patel (10.4%, Schedule 13D/A, filed 2026-03-04), Ray Prudo, M.D. (8.9%, Schedule 13D/A, filed 2026-03-04), Mmcap International Inc. Spc (8%, Schedule 13G, filed 2026-06-08) and Bank Of Montreal (5.71%, Schedule 13G, filed 2026-08-12); 1 more is listed above.
Who are the largest shareholders of Akari Therapeutics Plc?
By the share each holder's latest filing reports, the largest holders of Akari Therapeutics Plc on this page are Hoyoung Huh, M.D., Ph.D. (18.4%), Samir R. Patel (10.4%) and Ray Prudo, M.D. (8.9%).
When did Hoyoung Huh, M.D., Ph.D. buy into Akari Therapeutics Plc?
The filings give report dates, not purchase dates. The earliest filing from Hoyoung Huh, M.D., Ph.D. on this page is the Schedule 13G/A, filed 2026-03-04, reporting 18.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Akari Therapeutics Plc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Akari Therapeutics Plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Akari Therapeutics Plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Akari Therapeutics Plc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director and 10% owner: 140,805 shares (0.00% of shares outstanding) (Form 4, 2026-10-16).
- , a director: 76,861 shares (0.00% of shares outstanding) (Form 4, 2026-10-16).
- , the chief executive and a director: 41,173 shares (0.00% of shares outstanding) (Form 4, 2026-10-16).
- , a director: 38,877 shares (0.00% of shares outstanding) (Form 4, 2026-10-16).
- , a director: 36,271 shares (0.00% of shares outstanding) (Form 4, 2025-03-24).
Shares outstanding: 155,758,529,533 as of 2026-08-13, from the company's latest SEC cover page.
How much has Akari Therapeutics Plc raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-06-03 | $1.83M | $5.50M |
| Form D, 2025-10-24 | $6.25M | $6.25M |
| Form D, 2024-01-09 | $2M | $2M |
| Form D, 2023-10-19 | $1.97M | $1.97M |
Latest IPO step: Akari Therapeutics Plc amended its IPO registration (S-1/A, 2026-06-26).
IPO filings: S-1/A, 2026-06-26, RW, 2026-05-21, S-1, 2026-05-08, S-1, 2026-01-23, S-1, 2025-11-17; ticker AKTX on Nasdaq Capital Market.
Keep reading
More on Akari Therapeutics Plc and the records around it.
Akari Therapeutics Plc elsewhere on the record
- 5%+ stake filings Aug 2026
- Company profile and every filing Jun 2026
- Form D filing Jun 2026
- Form D filing Oct 2025
Companies that share a holder
- White Lion Capital LLC also filed stake reports on 4 other companies: Actelis Networks, Inc. (Jul 2026), CID Holdco, Inc. (Jun 2026), RELIANCE GLOBAL GROUP, INC. (Sep 2025)
- Bank of Montreal also filed stake reports on 49 other companies: Alarm.com Holdings, Inc. (Aug 2026), North American Construction Group Ltd. (Aug 2026), OPENLANE, Inc. (Aug 2026)
- MMCAP International Inc. SPC also filed stake reports on 52 other companies: BHAV Acquisition Corp II (Nov 2026), Haymaker Acquisition Corp V (Sep 2026), Thunder Bridge Capital Partners V, Ltd. (Aug 2026)
Related pages
Funding and filing history5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/akari-therapeutics-plc